Analysts at Noble Financial began coverage on shares of Nutriband (NASDAQ:NTRB – Get Free Report) in a report issued on Wednesday,Briefing.com Automated Import reports. The firm set an “outperform” rating and a $13.00 price target on the stock. Noble Financial’s target price suggests a potential upside of 81.03% from the company’s current price.
Nutriband Price Performance
Shares of NTRB stock opened at $7.18 on Wednesday. Nutriband has a 52 week low of $2.22 and a 52 week high of $9.60. The stock’s fifty day moving average is $4.44 and its 200-day moving average is $5.40. The stock has a market capitalization of $79.78 million, a PE ratio of -10.08 and a beta of 0.99. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.83 and a current ratio of 4.96.
Nutriband (NASDAQ:NTRB – Get Free Report) last posted its quarterly earnings results on Tuesday, December 3rd. The company reported ($0.12) earnings per share for the quarter. Nutriband had a negative return on equity of 54.49% and a negative net margin of 338.51%.
About Nutriband
Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.
Featured Articles
- Five stocks we like better than Nutriband
- The Role Economic Reports Play in a Successful Investment Strategy
- Tempus AI: A Game-Changer in AI-Powered Healthcare
- How to Find Undervalued Stocks
- Pelosi Bets Big on AI: This Is What You Need to Know
- What is Insider Trading? What You Can Learn from Insider Trading
- Mobileye’s High Short Interest Signals Squeeze Potential
Receive News & Ratings for Nutriband Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutriband and related companies with MarketBeat.com's FREE daily email newsletter.
